Dear Friends and Colleagues,

It gives us great pleasure to invite you to attend the 12^th International Congress on Myeloproliferative Neoplasms, to be held on October 24-25, 2019 in New York City.

Since the inaugural Congress in 2001, this meeting has become the premier forum for discussion on the latest advances in myeloproliferative neoplasms (MPNs). This year, the Congress will focus on timely topics of interest to hematologists and oncologists who treat patients with these rare disorders.

The Congress program format will utilize case presentations to highlight the essential features of MPN pathophysiology, diagnosis and management, as well as the roles of next generation sequencing and the MPN driver mutation and allele burden in clinical decision making. In addition to defining the role of pegylated interferon and its long-acting derivatives in MPN therapy, the role of immunotherapy in the MPNs and novel agents for MPN treatment will be reviewed

New this year will be a discussion of the management of accelerated and blast phase MPN, patient selection for bone marrow transplantation, and how to integrate MPN patient symptom scores with therapeutic planning.

Congress attendees will have the opportunity to participate in a variety of educational formats including didactic sessions, case reviews, poster sessions and oral abstract presentations, as well as multiple networking and one-on-one discussion opportunities. To allow more time for participant questions, time has also been allotted for a panel discussion with Congress faculty.

We look forward to welcoming you to New York City in October!

Warm regards,

Richard T. Silver, MD

Weill Cornell Medicine

New York, New York, USA

Chairman, 12th Intl Congress on Myeloproliferative Neoplasms

Jerry L. Spivak, MD

Johns Hopkins University School of Medicine

Baltimore, Maryland, USA

Co-Chairman, 12th Intl Congress on Myeloproliferative Neoplasms